Aligos Therapeutics reported second quarter 2026 results and recent business progress. The company received a $25 million upfront payment from Xiamen Amoytop Biotech for the exclusive Greater China license of pevifoscorvir sodium, plus a $3 million milestone triggered by IND approval for its ASO candidate ALG-170675 in China. Pevifoscorvir sodium completed enrollment in the Phase 2 B-SUPREME study and received Breakthrough Therapy Designation from China's NMPA. Aligos reported a net loss of $1.5 million, or $(0.14) per share, compared to a $15.9 million loss in the prior year period. Cash, cash equivalents, and investments totaled $30.4 million as of June 30, 2026, excluding the July upfront payment. The company stated its cash position provides sufficient funding through the fourth quarter of 2026. Aligos Therapeutics is a clinical-stage biotechnology company developing therapies for liver and viral diseases.

On June 25, 2026, Aligos Therapeutics, Inc. held its Annual Meeting of Stockholders. Stockholders approved an amendment to the 2020 Employee Stock Purchase Plan (ESPP) that reserves an additional 500,000 shares for issuance and eliminates the "evergreen" provision, which previously provided for automatic annual increases to the share reserve through 2030. The company also elected two Class III directors, Bridget Martell and Carole Nuechterlein, ratified Ernst & Young LLP as its independent auditor, and determined that future advisory votes on executive compensation will occur annually. Aligos Therapeutics is a biopharmaceutical company that develops therapeutic candidates for chronic liver diseases.